On Tuesday, KalVista Pharmaceuticals earned an upgrade to its Relative Strength (RS) Rating, from 70 to 73.
When To Sell Stocks To Lock In Profits And Minimize Losses
This proprietary rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if KalVista Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
KalVista Pharmaceuticals is now considered extended and out of buy range after clearing an 11.45 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
KalVista Pharmaceuticals posted 0% earnings growth in the latest quarterly report, while sales growth came in at 0%. Look for the next report on or around Sep. 4.
The company earns the No. 251 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Rigel Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
